[ad_1]
Litjen (L.J.) Tan, MS, PhD, chief strategy officer, Immunization Action Coalition, xxx
Nature Reviews: “The COVID-19 vaccine development landscape.” April 9, 2020.
Paul Offit, MD, director of the Vaccine Education Center and attending physician in the Division of Infectious Diseases, Children’s Hospital of Philadelphia.
David B. Weiner, PhD, executive vice president and director of the Vaccine & Immunotherapy Center, Wistar Institute, Philadelphia.
Esther Krofah, MPP, executive director, FasterCures, Milken Institute, Washington, D.C.
Commonwealth Fund Teleconference: “Coronavirus Science, Technology, and Policy: Vaccine Development.” April 17, 2020.
FDA: Emergency Use Authorization, updated April 22, 2020.
Colleen Hussey, spokesperson, Moderna Therapeutics.
Moderna press release: “Moderna Announced Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus,” April 16, 2020.
INOVIO press release: “INOVIO initiates Phase 1 Clinial Trial of Its COVID-19 Vaccine and Plans First Dose Today.” April 6, 2020.
CanSino Biologics Inc. press release: “CanSinoBIO’s Investigational Vaccine Against COVID-19 Approved for Phase 1 Clinical Trial in China.” March 17, 2020.
Chinese Clinical Trial Registry: “A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector). April 10, 2020.
Milken Institute: COVID-19 Treatment and Vaccine Tracker.
Maria Elena Bottazzi, PhD, co-director of the Texas Children’s Center for Vaccine Development at Baylor College of Medicine, Houston.
Oxford University: COVID-19 Oxford Vaccine Trial.
